ORASURE TECHNOLOGIES INC

Listed Company

OSURCIK 0001116463NasdaqAcceleratedSurgical & Medical Instruments & ApparatusDelawareFY ends Dec 31

Period

FY 2025

Revenue

$115.02M

Net Income

$-68.73M

Total Assets

$403.17M

Equity

$340.83M

Shares Out

69.13M

Op. Cash Flow

$-49.02M

Business

ORASURE TECHNOLOGIES INC develops, manufactures, markets and distributes diagnostic tests and sample management solutions that connect people to healthcare wherever they are. Its offerings include rapid point-of-care and OTC tests for HIV, HCV, COVID-19, Ebola and syphilis; molecular tests via Sherlock; collection devices and genomic and microbiome stabilization products; and immunoassays. A single business unit with commercial and innovation teams manages multiple product lines across diagnostics and sample management. The company sells products in the U.S. and internationally through direct sales, distributors, strategic partners, government agencies, clinical laboratories, clinics and retail channels.

Summary from filing dated 2025-03-07

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Total revenue	115	186	405	387	234
COST OF PRODUCTS AND SERVICES SOLD	67	106	234	239	116
Gross profit	48	79	172	148	118
Research and development	43	26	34	36	34
Sales and marketing	26	31	36	49	45
General and administrative	48	46	58	68	50
Loss on impairments	0	4	11	17	0
Change in the estimated fair value of acquisition-related contingent consideration	5	0	−99,000	−188,000	−1
Gain on sale of assets	−725,000	0	0	—	—
Total operating expenses	120	108	139	171	128
Operating (loss) income	−72	−28	33	−22	−10
OTHER INCOME	7	12	24	6	—
(Loss) income before income taxes and equity investment	−65	−16	56	−16	—
INCOME TAX EXPENSE	2	2	3	1	14
(LOSS) INCOME BEFORE EQUITY INVESTMENT	−66	−18	54	—	—
LOSS ON EQUITY INVESTMENT	−2	−2	0	0	—
NET (LOSS) INCOME	−69	−20	54	−17	−23
Basic earnings per share (in US dollars per share)	−0.94	−0.26	0.73	−0.24	−0.32
Diluted earnings per share (in US dollars per share)	−0.94	−0.26	0.72	−0.24	−0.32
Basic weighted average number of shares outstanding (in shares)	73	74	73	73	72
Diluted weighted average number of shares outstanding (in shares)	73	74	74	73	72

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	199	268	290	84	117
Accounts receivable, net of allowance for doubtful accounts of $188 and $774	22	24	40	71	45
Inventories	31	34	48	96	53
Prepaid expenses	5	4	6	6	8
Other current assets	4	3	2	42	40
Total current assets	262	333	386	325	299
Property, plant and equipment, net of accumulated depreciation	39	45	45	59	73
Operating right-of-use assets, net	12	13	12	10	9
Finance right-of-use assets, net	146,000	145,000	576,000	1	2
Net	19	17	1	—	—
Goodwill	43	40	36	35	40
Investment in equity method investee	26	28	0	—	—
Deferred tax asset	271,000	156,000	0	—	—
Other noncurrent assets	1	2	1	1	5
Total noncurrent assets	141	146	96	119	162
TOTAL ASSETS	403	480	483	444	461
Accounts payable	7	8	13	38	28
Deferred revenue	2	3	2	2	3
Accrued expenses and other current liabilities	11	20	23	26	34
Finance lease liability	63,000	41,000	539,000	1	939,000
Operating lease liability	2	2	2	2	2
Current portion	18	0	0	65,000	206,000
Total current liabilities	40	33	40	69	68
Finance lease liability	100,000	113,000	226,000	503,000	2
Operating lease liability	11	12	11	9	7
Long-term portion	9	23	0	99,000	354,000
Other noncurrent liabilities	2	494,000	696,000	581,000	651,000
Total noncurrent liabilities	23	36	13	11	12
TOTAL LIABILITIES	62	69	52	80	80
Commitments and Contingencies	—	—	—	—	—
Preferred stock, par value $0.000001, 25,000 shares authorized, none issued	0	0	0	0	—
Common stock, par value $0.000001, 120,000 shares authorized, 70,391 and 74,598 shares issued and outstanding	0	0	0	0	0
Additional paid-in capital	531	538	530	520	511
Accumulated other comprehensive loss	−18	−24	−15	−18	−10
Accumulated deficit	−172	−103	−84	−138	−120
Total stockholders' equity	341	410	431	364	381
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	403	480	483	444	461

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Stock-based compensation	10	12	11	12	8
Depreciation and amortization	10	11	21	15	12
Other non-cash amortization	−222,000	−564,000	3,000	228,000	837,000
Provision for credit losses	−65,000	71,000	−462,000	−1	−253,000
Unrealized foreign currency loss (gain)	365,000	−263,000	103,000	−161,000	−210,000
Interest expense on finance leases	8,000	22,000	51,000	94,000	82,000
Deferred income taxes	2	−657,000	102,000	−2	1
(Gain) loss on sale of fixed assets	−725,000	563,000	0	—	—
Payment of acquisition-related contingent consideration	0	0	−19,000	0	−142,000
Accounts receivable	2	16	31	−25	−6
Inventories	4	13	48	−43	−21
Prepaid expenses and other assets	−2	4	−2	−7	−9
Accounts payable	−2	−8	−27	3	3
Deferred revenue	−2	−219,000	−730,000	−596,000	−2
Accrued expenses and other liabilities	−9	−6	−3	1	3
Net cash (used in) provided by operating activities	−49	27	142	−47	−35
Purchases of short-term investments	0	−53	−75	−23	−26
Proceeds from maturities and redemptions of investments	0	53	102	47	68
Purchase of equity method investee	0	−30	0	0	—
Acquisition of business, net of cash acquired	−4	−5	0	0	—
Proceeds from sale of assets	1	0	0	121,000	0
Purchases of property and equipment	−4	−4	−6	−7	−22
Purchase of property and equipment under government contracts	0	0	−5	−57	−26
Proceeds from funding under government contracts	0	0	49	60	531,000
Net cash (used in) provided by investing activities	−7	−39	66	21	−6
Cash payments for lease liabilities	−61,000	−842,000	−1	−1	−686,000
Proceeds from exercise of stock options	0	200,000	300,000	20,000	246,000
Repurchase of common stock	−15	0	0	−2	−2
Payment of acquisition-related contingent consideration	0	0	46,000	−208,000	−264,000
Payment of taxes related to net share settlement of equity awards	−2	−4	−2	—	—
Net cash used in financing activities	−17	−4	−3	−4	−3
EFFECT OF FOREIGN EXCHANGE RATE CHANGES ON CASH	4	−7	2	−3	−340,000
NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS	−68	−23	206	−33	−44

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro